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1. Introduction
Today great hope is set on regenerative medicine in all medical fields. Leland Kaiser intro‐
duced the term “Regenerative Medicine” in 1992. He forecasted that a “new branch of medicine
will develop that attempts to change the course of chronic diseases and in many instances will
regenerate tired and failing organ systems” (Kaiser, 1992). Since then, scientists all over the
world try to develop cell-based approaches to regenerate damaged tissues, or even substitute
whole organs (Ehnert et al., 2009).
Degenerative disease of articular cartilage (AC), generically known as osteoarthritis (OA),
is  an  irreversible  evolution  process  towards  terminal  articular  failure.  Due  to  its  high
prevalence  on  population  and  its  socioeconomic  impact,  this  condition  is  of  great  con‐
cern, and this way more resources and effort are dedicated to the research on its develop‐
ment.  Cartilage  tissue  engineering  seeks  to  combine  cells,  biomaterial  scaffolds,  and
bioactive  signals  to  create  functional  tissue  replacements  to  treat  cartilage  injuries  or
osteoarthritis (Song et al., 2004).
Cartilage degenerative disease, OA, is the end stage of several conditions such as trauma,
inflammatory diseases, overweight etc. The fatalistic theory that states that it  is impossi‐
ble  to  recover  the  cartilage once it  has  been damaged leads to  the  assumption that  the
progression to any form of OA is unavoidable (Fig. 1). The annual incidence of young adults
suffering  any cartilage  injury  in  UK is  10000  and this  figure  is  continuously  increasing
(NICE, 2008).
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Figure 1. Osteochondral injury in a femoral head from a surgical intervention in our hospital
The new patient does not accept a reduction in his demands and quality of life because of the
OA as the culmination of an articular injury during sport activity. On the other hand, a higher
risk for developing degenerative disease and obesity, mainly knee arthritis, has been corre‐
lated. The symptomatic cohort of pain, swelling, range of motion diminution and loss of quality
life can only be partially recovered by a total joint replacement (Fig. 2).
Unfortunately, joint replacement is neither a procedure free of complication nor a forever-
realistic  solution.  It  is  expected  that  by  the  year  2030  the  number  of  total  hip  or  knee
replacement implanted annually will  be respectively 1.8 and 7 times the current figures
(Kurtz et al.,  2007). It is doubted that such an economic impact could be ever be afford‐
ed. Finding an alternative option to manage these lesions will be a challenge and this must
be closer to achieve an almost AC tissue able to bear the requirements of an active long
period of life.
AC is a quite simple structure with scarce cellularity within an extracellular matrix (ECM).
However, in spite of this simplicity, its structure and performance is very complex.
The ability of the AC to heal these injuries on its own is almost none. The lack of blood supply
is the main handicap this tissue has at the time of healing. Without vessels the preliminary
inflammatory step of the healing process is not possible. To start with, the dead tissue needs
to be removed and the flood of new cells from the vascular stream is essential for this.
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Furthermore, the cell mediators will not appear as the granulocytes are not present and the
degranulation of these is its source. Secondly, the chondrocytes are well-differentiated cells
with a limited capacity to produce ECM. This is sufficient to cover the necessities of a still
cartilage turnover but not to cope with the healing of a traumatic defect.
In any case, if the trauma produces a lesion that breaches the subchondral plate, it allows access
to the vascular network and the final produced tissue is made of collagen type I, more resistant
to tension, instead of type II, more resistant to compression.
1.1. How can this be sorted out?
Several attempts have been made in order to repair the traumatic defect and to achieve a
regeneration of the original injured cartilage.
Figure 2. Treatment of a OA by total joint replacement performed in our hospital
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A first group of interventions can be described as “marrow stimulating techniques”. Drilling
the defect beyond the subchondral plate is its essential and allowing a repair promoted by the
bleeding from the subchondral bone creating a “super clot” its rationale (Mithoefer et al.,
2005). The star cells here are the mesenchymal stem cells (MSCs) emerging with the hematoma
and its subsequent proliferation and differentiation. Unfortunately, the final result is the
promotion of a fibrous tissue not durable in time (Steret et al., 2004). Pridie et al. promoted this
concept in 1959. Abrasion arthroplasty (Steret et al., 2004), microfracture (Steadman et al.,
2003), or Autologous Matrix Induced Chondrogenesis (Gille et al., 2010) have been more
recently developed with the same rationale.
In essence, previous treatments have attempted to promote the healing of the damaged
reminding nature. That is to say, allowing the flood of blood from the inner areas of the
subjacent bone. Unfortunately, this will promote a scar tissue that in the long run will be lost
and the joint degenerative process will be stated (Kreuz et al., 2006).
In a second group of interventions, it is proposed the articular defect to be covered by a
“replacement technique”. In these, the defect is reshaped to a standard cylindrical way and
substituted with a plug of osteochondral graft harvested from a non-weight bearing donor site.
Using this technique two handicaps can be appreciated: the limited available graft and the
morbidity of the donor site. Additionally, the differences in characteristics between the donor
and the receiver areas may impede a complete integration. This may be the reason why the
clinical results have not been in accordance with the initial enthusiasm (Mishima et al., 2008).
Both, auto- and fresh allograft (Gross et al., 2002) have been attempted with the name of
mosaicplasty.  With the aim of avoiding the donor site morbidity,  synthetic reabsorbable
scaffolds have been used to fill up the osteochondral defect. A “toast and butter” cylinder,
engineered mimicking components, bone and cartilage. In contrast with the graft, this scaf‐
fold will have osteoconductive properties instead and eventually resorb in 12 months. The
pseudo-cartilage now created will be poorly incorporated and the biomechanics will fail (Yasen
et al., 2012).
The third group of proposed interventions are cellular-based. The aim in this alternative option
is producing a regeneration of the cartilage mediated by the own patient chondrocytes. This
is a two-stage procedure. During the preliminary intervention a biopsy from the cartilage is
obtained and then the chondrocytes are isolated and cultured till the number of cells is about
fifty folds. For the second intervention, ex vivo expanded chondrocytes are implanted in the
damaged area. This procedure has evolved with the aim of getting a watertight seal environ‐
ment in order to receive the chondrocytes and avoid the leakage. First, it was attempted a sheet
of periosteum, then a collagen gel and a collagen membrane has been developed. But, are the
delivered chondrocytes, the MSCs coming from the subchondral bone or the cells evading
from the layer of periosteum the source for promoting the repaired tissue?. In spite of the
rationale of this techniques, the autologous chondrocytes implant has not finally reached the
expected results, the final tissue obtained was fibrous instead of AC (Tins et al., 2005) and
hence, the OA is once more the undesirable expected long-term result (Hunziker, 2002;
Temenoff et al., 2000).
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2. Therapeutic interventions without active biologics
2.1. Bone marrow stimulation
First approaches to heal cartilage by in situ regeneration date back to 1959. Pridie technique
was directed to BM cells recruitment to be used in cartilage defects by drilling small holes into
the subchondral BM space underlying the damaged cartilage regions. It was improved later
on by reducing the size of the perforations and being then called microfracture technique which
is now a frequently performed and well-studied procedure (Steadman et al., 1999). This
technique is based on the mechanism of mesengenesis or capacity of the non-differentiated
mesenchymal cells in choosing a determined phenotype as a response to inducing or GFs. A
non-differentiated cell from the BM can be promoted to different cell types such as osteoblasts,
with a later maturing to osteocytes, chondroblasts and chondrocytes, but also to endothelial
cells, mesothelial cells, fibroblasts or adipocytes. It is a cell signalling process of local cytokines
on local cells. In order to achieve all this, the surgical technique is based on drilling the
subchondral plate to get bleeding and a superclot that will become a scaffold and supply cells
and proteins, starting this way the physiological cascade of the chondrogenic cell differentia‐
tion. Other alternative techniques of BM stimulation to regenerate cartilage would be abrasion
chondroplasty and in case the articular surface remained untouched, the retrograde stimula‐
tion technique. Cartilage defects are repaired only with fibrous tissue or fibrocartilage when
using these methods, probably because the number of chondroprogenitors recruited from the
BM is too small to promote the hyaline cartilage repair and results are often followed by
degeneration of the repair tissue. This was used as an explanation for the observations of other
studies that good short term results may be followed by deterioration starting about 18 months
after surgery.
Clinical observations and theoretical considerations pointed towards several possible limita‐
tions of marrow stimulation techniques. The non-adhesive properties of the cartilage surface
and the softness and shrinking of the superclot can lead to only partial defect filling and
facilitate an early loss of repair tissue from the cartilage lesion. To avoid this, the treatment has
been recently advanced into a matrix-supported technique in which the performed defect was
stabilized in an additional way with a biomaterial. The microfractured lesion is covered with
a collagen type I ⁄ III scaffold and it is called autologous matrix induced chondrogenesis (AMIC)
(Kramer et al., 2006; Steinwachs et al., 2008). This technique has been developed to allow the
treatment of larger defects by microfracturing and it is used as alternative treatment to
autologous chondrocytes transplantation (ACT).
2.2. Autologous osteochondral transplantation: Mosaicplasty
Autologous osteochondral mosaicplasty, sometimes known as osteoarticular transfer system,
OATS, is an effective method for the resurfacing of osteochondral defects of the knee. The
technique consists in transplantation of many osteocondral autologous plugs obtained from
the periphery of the femoral condyle articular surface, which supports less weight and
transferring them to create a durable resurfaced area in the defect (Fig. 3). The procedure shows
some advantages regarding other repair techniques, such as the viable hyaline cartilage
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transplantation, a relatively short rehabilitation period and the possibility of carrying out the
procedure in one only operation.
 
Figure 3. In mosaicplasty cylindrical osteochondral plugs are harvested from nonload-bearing sites in the affected
joint and pressed into place within the osteochondral defect, creating an autograft “mosaic” to fill the lesion
However, the OATS limitations are the donor-site morbidity and a limited availability of grafts
that can be obtained from the femoropatellar joint or the area adjacent to the intercondylar
fossa. Other possible limitations are differences in bearing, thickness and mechanical proper‐
ties between the donor’s and the receiver’s cartilages, as well as the graft sinking into the
surface due to the support of weight after surgery. Besides, the lack of filling and the possible
dead space between cylindrical grafts can limit the repair quality and integrity. Lane et al.
transplanted autologous osteochondral grafts into sheep knee joints and reported the lack of
integration of the cartilage, which determined the persistence of gaps through the full thickness
in all the specimens (Mishima et al., 2008).
2.3. Alogenic osteochondral transplantation
Osteochondral allograft transplantation is a procedure for cartilage resurfacing which involves
the transplantation into the defect a cadaveric graft composed of viable, intact AC and its
underlying subchondral bone. It is a well known resource, especially for tumour surgery. The
defect size, its location and its depth are crucial factors for the suitability of the donor graft.
Advantages of using osteochondral allografts are the possibility if achieving a precise archi‐
tecture of the surface, the immediate transplantation of viable hyaline cartilage in a one-time
procedure, the possibility to repair large defects, even half-condyles and the donor-site lack of
morbidity. Gross et al. have reported results from fresh allografts in 123 patients with good
clinical results in 95% of the patients after five years (Gross et al., 2002). There are different
possible allografts. Fresh osteochondral allografts are generally used because both freezing
and cryopreservation have proved to reduce the chondrocytes viability. Traditionally grafts
have been obtained, kept in lactated Ringer’s solution at 4 °C and then transplanted in a week.
Another alternative for allografts conservation and implantation is cryopreservation, which
involves freezing at a controlled speed of specimens within a nutrients rich medium, a
cryoprotector agent (glycerol or dymethil sulfoxide), to minimize the cells freezing and keep
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their viability; finally, there is the possibility of fresh-frozen allografts, with the advantages of
lower immunogenic capacity and less transmission of diseases but with lower chondrocyte
viability.
2.4. Soft tissues transplantation
Two main theories support the practicing of covering the cartilage defects with soft tissues,
such as perichondrium or periosteum. On one hand, the defect has to be covered mechanically
and on the other, we know about the presence of pluripotential stem cells in the perichondrium
and the periosteum cambium layer. The different factors able to promote these cells differen‐
tiation into active chondrocytes still remain unknown.
3. Therapeutic interventions with active biologics
3.1. Autologous chondrocytes implant
The clinical use of the autologous chondrocytes implant (ACI) technique was first reported by
Brittberg et al. in 1994, following animal studies which had shown its effectiveness (Grande et
al., 1989). In this method, chondrocytes are obtained from a biopsy taken from a non-weight
bearing part of the patients cartilage, and are expanded in vitro, followed by the injection of a
suspension of chondrocytes into cartilage defects, covered with autologous periosteal flap (Fig.
4). This technique premises are based on the capacity of adhesiveness of the cells to certain
surfaces, they spread on them and proliferate producing their specific ECM. Although clinical
results of the original ACI looked promising (Minas, 2001; Peterson et al., 2000), this procedure
has some potential disadvantages, such as leakage of transplanted cells, invasive surgical
method, hypertrophy of periosteum (Haddo et al., 2005; Kreuz et al., 2009) and loss of
chondrogenic phenotype of expanded chondrocytes in monolayer culture (Benya & Shaffer,
1982). Second generation ACI, named membrane autologous chondrocyte implantation
(MACI), has a similar procedure, but a collagen type I and III membrane instead of periosteum.
This technique was introduced to improve the ACI problems, and biomaterials such as
collagen type I gel (Ochi et al., 2002), hyaluronan-based scaffold (Manfredini et al., 2007) and
collagen type I/III membrane (Bartlett et al., 2005) were applied to secure cells in the defect
area, to restore chondrogenic phenotype by way of three dimensional cultures (Gigante et al.,
2007]) and to replace the periosteum as defect coverage. This is the way MACI technique is
created a posteriori, by implanting autologous chondrocytes in three dimensional matrices of
collagen types I and III, or hyaluronic acid.
At present, only two prospective studies comparing the original and second generation ACI
are available (Bartlett et al., 2005; Manfredini et al., 2007) and both studies show no significant
differences in the short term clinical results. As for the first generation ACI, the newly
regenerated cartilage often consists of fibrous tissue (Horas et al., 2003; Tins et al., 2005),
possibly due to the limited number of chondrocytes and their low proliferation potential. Bone
overgrowth that causes thinning of the regenerated cartilage and the violation of the tidemark
are also of concern. Moreover, this method still sacrifices healthy cartilage. Thus, these aspects
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limit ACI in the treatment of large defects and may increase the long-term risk of osteoarthritis
development.
3.2. Are Mesenchymal Stem Cells what we need?
Stem cells are of particular interest in Regenerative Medicine. They inhere several unique
characteristics that distinguish them from other cell types. Besides autograft transplantation
and ACI, current therapeutic concepts of cartilage defects include the recruitment of MSCs.
Tissue engineering (TE) based on cell and genetic therapy offers some of the most promising
strategies of tissue repair, including AC repair. It is the science able to create alive tissue to
replace, repair or strengthen ill tissue. Thus, the TE refers to a wide variety of techniques.
The process for using MSCs to produce cartilage tissue comprises four elements: cells, inductor
factors, scaffold to deliver the cells and vascular supply to the host area.
From the previous experiences we have learned that we need:
• To minimize the risk and inconveniences of the donor site. In this case, MSCs are easily
available from bone marrow, synovial membrane, adipose tissue, etc. So then, we can get a
variable number of cells from a different tissue, partially avoiding the donor site secondary
complication (Winter et al., 2003). In ACI, this extra procedure adds a risk for infection,
inflammatory changes in the joint, pain and rises up the final cost of the treatment (Hunziker,
2002)
• To achieve a minimum number of cells. MSCs have a high proliferation and differentiation
potential. In any case, MSCs coming from different tissue have an uneven chondrogenic
Figure 4. In autologous chondrocytes implantation (ACI) a chondral biopsy is taken from a donor site at the time of
clinical examination to be treated with enzymes in the laboratory to obtain chondrocytes cultures that are re-injected
under the periosteal flap
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differentiation capacity and it must be related to the special cytokines, growth factor and
induction molecules composition of the medium (Claros et al., 2012; Hennig et al., 2007). To
induce the differentiation of predifferentiated cells, MSCs, is a more controlled way of
driving the process to a cartilage final effector. One of the cons of chondrocyte transplan‐
tation is the dedifferentiation process that these cells suffer when they are treated in vitro
and the limited ability to redifferentiate them (Benz et al., 2002). On the contrary, MSCs are
very stable and they do not suffer this dedifferentiation (Najadnik et al., 2010) process and
have a high differentiation capacity.
Up to now, MSCs have been used to treat osteochondral defects in two different ways. We
have the option of implanting the MSCs once expanded. It is of concern in this case the lack of
control on the growth after transplantation and how much exhausted the cells will result after
the expansion and how it will influence on the aging of the new induced tissue. The clinical
results after implantation of these expanded MSCs have been analysed and were substantially
the same compared with those obtained after any marrow stimulating techniques (Wakitani
et al., 2002; López-Puerta, 2013). A second option is to implant the MSCs after the induced
differentiation to a chondrocyte phenotype. In these circumstances, to assure the stability of
the achieved phenotype is of concern as this lineage is able to go on with the complete chondral
process and ends in producing final stages of hypertrophy and calcification (Pelttari et al.,
2006; Andrades et al., 2010; López-Puerta, 2013). In any case, the final challenge will be to
produce a stable cellular lineage that produces an AC tissue that works under compression
forces without losing its initial characteristics as time goes by.
Beside the characteristics of MSCs exposed before, these cells have self-renewal potential as
well as multilineage differentiation potential (Becerra et al., 2011), including chondrogenesis
(Johnstone et al., 1998; Pittenger et al., 1999; Prockop 1997; Sacchetti et al., 2007). MSCs
chondrogenesis was first reported by Ashton et al. (1980) and the first ones to describe a defined
medium for in vitro chondrogenesis of MSCs were Johnstone et al. (1998), who used micromass
culture with TGF-β and dexamethasone. Sekiya et al. (2001, 2005) reported that addition to
bone BMPs enhanced chondrogenesis under the conditions employed by Johnstone et al.
(1998). Nowadays, the micromass culture is widely used to evaluate chondrogenic potential
of MSCs in vitro. However, this in vitro chondrogenesis does not mimic cartilage formation
during development. During micromass culture, MSCs increase expressions of both collagen
type II (chondrocytes marker) and X (hypertrophic chondrocytes marker) (Barry et al., 2001;
Ichinose et al., 2005). Other cytokines such as IGF (Pei et al., 2008) and parathyroid hormone-
related peptide (PTHrP) had been tried for better differentiation cocktails, but it is still difficult
to obtain in vitro MSC-based cartilage formation comparative to native cartilage tissue.
To initiate any regeneration based on MSCs activity, the cells first have to be recruited to the
site of damage (Fig. 5). Second step is adhesion to a local matrix followed by activation and
extensive proliferation to provide the necessary high numbers of chondroprogenitor cells to
build up new tissue. In stem 3, the cells need to switch from expansion to chondrogenic matrix
production by induction of chondrogenesis to build up the shock absorbance and gliding
characteristics for proper tissue function. The seamless integration with neighbouring cartilage
and bone tissue depends on successful crosstalk between new and old tissue, and an instruc‐
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tional capability to guide neighbouring cells. For durable cartilage regeneration, the tissue
eventually needs to regenerate a tidemark, adapt to biomechanical loading and build up a
balanced tissue homeostasis. We are going to summarize these steps including talking points
taken from our annual meetings in NACRE (New Approaches for Cartilage Regeneration;
CIBER-BBN, Spain) consortium, in order to propose strategies for the Regenerative Medicine
of AC (Becerra et al., 2010; Andrades et al., in press)
Figure 5. Principal mechanisms for in vivo cartilage regeneration. 1) MSCs recruitment from the surrounding tissues
such as synovial fluid/membrane, neighbors cartilage, or subchondral bone; 2) MSCs retention by local adhesion, and
proliferation; 3) MSCs are induced to chondrogenic differentiation by local factors; 4) chondroblasts and chondrocytes
arranged according to the cartilage zones pattern and biomechanical loading; 5) integration of repair tissue interac‐
tion with cartilage and subchondral bone
3.2.1. Recruitment of MSCs
Cell migration is a prerequisite for development from conception to adulthood and plays a
major role in regeneration of all tissues. Even articular chondrocytes, which are encased in a
dense matrix throughout their life, can show cell motility when transferred in vitro. A number
of studies demonstrated that chondrocytes migrate under the action of different stimuli on or
within planar and 3D matrices. Attracting factors include bone morphogentic proteins (BMPs)
(Frenkel et al., 1996), insulin-like growth factor-one (IGF-1), transforming growth factor-beta
(TGF-β), fibronectin (Andrades et al., 2003: Chang et al., 2003), plateled-derived growth factor
(PDGF) (Fujita et al., 2004), fibroblast growth factor (FGF) (Hidaka et al., 2006), fibrin and
collagen type I (Kirilak et al., 2006).
But, what are the best factors to attract more MSCs to a cartilage lesion? Recent work has
established that MSCs are not largely distinct from chondrocytes regarding the panel of factors
capable to attract the cells in vitro. All tested factors were further effective in stimulating the
migration of MSCs but not fibroblasts (Ozaki et al, 2007). Factors contained in a natural blood
clot are highly chemoattractive for MSCs; augmentation of a clot-stabilizing matrix with a
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potent chemoattractive factor like PDGF may be an attractive way to further enhance cell
numbers early after microfracturing.
In this sense, a quick release kinetics within hours and days from the biomaterial is desired for
this first step of healing. Unfortunately, no 3D in vitro model in a biomatrix has yet been applied
to test chemoattraction of human MSCs under more natural conditions and no adequate animal
model has been used to dissect the factor requirement of progenitor cell recruitment from bone
marrow into cartilage defects. Most likely, the presence of synovial fluid and the joint loading
initiated pumping mechanism will strongly affect attraction and retention of MSCs. A search
for superior factor combinations to enhance and speed up MSC attraction, and the best
retention matrix to keep cells local, thus, is an important topic for upcoming studies.
3.2.2. Multiplication of MSCs
Proliferation of MSCs is the second important step to rapidly enhance the cell numbers in the
repair tissue. As the replicative lifespan of MSCs is, however, not unlimited and telomerase
activity is absent or low (Parsch et al., 2004) this can only ground on the sufficient attraction
of initial MSCs numbers to the defect. During embryonal development proliferative chondro‐
progenitors are densely packed and condensed to an area in which cartilage tissue is forming.
The high cell numbers may be needed to deposit the vast amount of ECM characterizing this
tissue. Low cellularity of AC is rather a late phenomenon during tissue formation and may
have developed in adaptation to its biomechanical competence and the extremely slow
turnover of its ECM. Proteoglycan turnover in cartilage is up to 25 years and collagen half-life
was estimated to range from several decades up to 400 years (Eyre et al., 2006). Based on the
assumption that embryonal traits should best be recapitulated during tissue regeneration,
early defect filling tissue should contain densely packed proliferating chondroprogenitors.
This would mean that rather hundreds of millions of new cells are needed per cm3 during this
step in the defect to allow for optimal chondrogenesis and rapid ECM production. At a later
phase, cell numbers could decline to a density of 5-10 million cells per gram tissue, when
homeostasis is the left over task for the cells in the fully regenerated tissue.
These points towards an outstanding need for highly efficient transient induction of prolifer‐
ation, a typical feature ascribed to adult stem cells. Growth requirements of human MSCs are
distinct from those of other species (Kuznetsov et al., 1996) and many factors have been
identified as potent mitogens, being PDGF-BB, EGF and TGF-β have been regarded as the most
important amongst them (Kuznetsov et al., 1997). As they induced the migration of MSCs and
have at the same time the potency to enhance their proliferation, the migration and prolifera‐
tion steps of MSCs can take place simultaneously in vivo. However, whilst nutrients and
oxygen are almost unlimited in tissue culture, a rapid supply of cells with O2 and nutrients
may be more restricted in a cartilage defect and depend on the distance to and conditions found
within the subchondral bone. Histology of early human cartilage repair tissue demonstrates
that indeed cartilage differentiation initiates in contact with subchondral bone (Steck et al.,
2009) whilst upper regions remain fibrous for quite a long time and may need to mature over
years (Brun et al., 2008). Furthermore, earliest chondrogenesis is often seen in areas where
active remodeling of the subchondral bone plate occurs and, thus, enhanced nutrition and a
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higher anabolic rate of the cells can take place. Beside strong mitogenic factors used for
augmentation of a clot-stabilizing biomaterial, the access to optimal nutrition in the course of
tissue remodeling may indeed be a limiting aspect of cartilage regeneration techniques.
Enhanced remodeling of microfractured compared with unopened subchondral bone areas is
likely, but quantitative and localization-dependent studies have so far not been reported. The
stimuli mentioned here could be obtained by direct administration of recombining growth
factors in the culture media or via transfer of the respective genes. Thus, the possibility of
considering genetic therapy as an applicable measure for the treatment of cartilaginous lesions
arises.
4. The recapitulation of AC morphogenesis through MSCs differentiation
In spite of therapeutic strategies mentioned, which offer the patient a temporary relief of
symptoms, they do not resolved, in the medium or long term, the disease that affects the joint.
In most cases, fibrocartilage is generated that does not provide the necessary structural
integrity and this often results in the subsequent replacement of the damaged joint (Mahmou‐
difar and Doran, 2012).
The main problem with these strategies is that only tries to restore the biomechanical charac‐
teristics of tissue but not its physiology. That is why the goal of current research in AC
regeneration with MSCs is moving to methods that attempt to recapitulate the morphogenesis
of the tissue. The challenge is to develop strategies that will cover the widest possible range
of intervening factors including: the dynamics of genes and proteins that control and partici‐
pate in the chondrogenic process, their spatiotemporal patterns of expression, variations in
culture conditions, biomaterials functionalized with effector molecules inducers of chondro‐
genesis and the inclusion of differentiation enhancers using genetic engineering and others.
4.1. Novel genes and protein: The path to recapitulating AC morphogenesis
As previously mentioned, the AC’s ECM is composed mainly of collagen type II fibers and
proteoglycans with strong negative charges, aggrecan being the most abundant of them (Han
et al, 2011). That is why the detection of both proteins and their corresponding genes has been
classically used as markers of chondrogenesis in numerous studies in vitro and in vivo. However,
most modern regenerative strategies should aim at obtaining a more complete and organized
ECM that achieves the greatest similarity with the ECM on the original AC. With this objec‐
tive, have been identified dozens of genes that play a fundamental role in the formation and
maintenance of AC, which are potential targets for research in the design of regenerative
strategies (Quintana et al., 2009; Bobick et al., 2009; Mahmoudifar and Doran, 2012).
4.1.1. Proteoglycan 4 (PRG4): Biological function and its relationship to OA
A good example is the proteoglycan 4 (PRG4), also known as "superficial zone protein" (SZP)
and “lubricin”. It is a proteoglycan specifically synthesized by chondrocytes located at the
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surface of AC and by synoviocytes. Their functions are the lubrication of articular joints, elastic
absorption and energy dissipation of synovial fluid (Jay et al., 2007).
It has been shown that mutant mice Prg4-/ - have normal joints at birth and during the newborn
period but older mice exhibit accumulation of proteinaceous deposits on the cartilage surface,
disappearance of the surface zone of flattened chondrocytes, synoviocyte hyperplasia,
calcification of structures flanking the ankle joints and, consequently, a total failure of the joint
(Coles et al., 2010). These data are consistent with OA degeneration, and have also been
observed in veterinary cases of sheep with early OA which has been shown a downregulation
of the expression of PRG4 (Young et al., 2006). In a human clinical example, a case study
reported in 2004 a 10 year old boy with Camptodactyly-Arthropathy-Coxa vara-Pericarditis
syndrome (CACP) which arises as a result of truncating mutations of this gene. Clinical
manifestations of CACP include congenital or early-onset camptodactyly, noninflammatory
arthropathy with synovial hyperplasia and progressive coxa vara deformity, all symptoms
related with the cartilage’s physiology (Choi et al., 2004).
All these studies show that PRG4 is closely related to morphogenesis, maintenance and
functioning of the AC as well as defects in its expression are related to the development of OA.
That is why in recent years has aroused interest in the field of in vitro studies as a potential aim
in developing AC regenerative strategies.
4.1.2. PRG4: An in vitro, in vivo and clinical marker of chondrogenesis
Several studies show that this protein participates in the chondrogenic process and that its
expression can be induced on in vitro chondrogenesis experiments. Recently, has been found
an increase in PRG4 gene expression in cells derived from infrapattelar fat pad (IFP) in response
to treatment with TGF-β1 and BMP-7, demonstrating that the in vitro induction of this gene
expression is possible. Furthermore, it served to demonstrate the suitability of the source cell
used (Lee et al., 2008). However, the same research group in a similar characteristics experi‐
ment but using human embryonic stem cells (hESC) was able to induce chondrogenesis but
failed inducing PRG4 expression, concluding that the induction conditions should be opti‐
mized. PRG4 use as a marker allowed the discrimination of both experiments (Nakagawa et
al., 2009). It has also been observed that in rat skeletal muscle-derived mesenchymal stem/
progenitor cells (MDMSCs) treated with TGF-β1 and BMP-7, PRG4 increased in a time-
dependent manner on days 3, 7 and 10. As early as day 3, there was a three-fold increase of
the PRG4 detected by ELISA analysis. This was confirmed by immunochemical localization of
PRG4 as early as day 3 after treatment with TGF-β1. Even, the mRNA expression of PRG4 was
enhanced by the two factors, along or in combination. This work demonstrates that is possible
induce in vitro not only the increased of PRG4 gene expression, but also the accumulation of
the protein in the medium (Andrades et al., 2012).
In clinical setting, there are also studies related with PRG4. Patients with OA tend to form
small cartilaginous deposits in the exposed subchondral bone. The histological study of
aggregates of patients undergoing total knee replacement, reveals that these aggregates were
fibrocartilaginous, positive staining for glucosaminoglycan Safranin-O and type II collagen
expression but, more interestingly, of PRG4. In those aggregates embedded in the bone, the
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staining was positive for the entire surface while in which protruded to the surface, the PRG4
was detected only in the edge surface as would be observed in normal cartilage. This in vivo
observation is an excellent example of the cell’s genetic response to the environment. Osteo‐
chondroprecursors contact with the synovial fluid and physicochemical stimuli inherent to
the articular surface is able to modify the spatial distribution patterns of PRG4 expression and
thus, the tissue architecture. These results are an invitation to test culture conditions that
attempt to emulate not only the biochemical environment, but also mimic the biophysical
characteristics of the physiological niche (Zhang et al., 2007) (Fig. 6).
Figure 6. A) Probe pointing to a white spot on the exposed bone surface of an osteoarthritic femoral condyle ob‐
tained at the time of total knee arthroplasty. B) Immunohistochemistry for PRG4 to subsurface chondrocyte aggregate
in subchondral bone staining fully for PRG4; and C) fibrocartilaginous deposit protruding through the joint surface
containing PRG4 in a zone just below the surface. From the same authors, published by Journal of orthopaedic re‐
search: official publication of the Orthopaedic Research Society 25(7): 873–883. Copyright 2007
It has also been demonstrated the possibility of reversing the decline in the expression of PRG4
in cartilage chondrocytes culture from OA patients. In this study, cartilage explants were
obtained from healthy and OA patients and performed monolayer cultures and encapsulated
in poly (ethylene glycol) diacrylate scaffold (PEG-DA). The OA cartilage explants have weaker
inmunolabeling of PRG4 than healthy cartilage explants. However, the difference was reduced
significantly between these 2 samples when were cultured in PEG-DA hydrogels. OA chon‐
drocytes regain the ability to express PRG4 at levels virtually identical to those obtained in
chondrocytes from normal cartilage demonstrating the importance of culture conditions in the
condrogenic induction (Musumeci et al., 2011).
All these evidences indicate that the inclusion of proteins as PRG4 in experimental designs
offers advantages such as:
1. The inclusion of more highly specific markers that allow a better understanding of
chondrogenic potential of cell sources, bioactive scaffolds and treatments applied.
2. Implant design that better mimic the characteristics of the AC and try to emulate not only
the composition but also tissue architecture.
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3. The ability to understand more deeply the dynamics of diseases that affect the AC like
OA, in order to raise regenerative strategies that offer to patients, medium and long term
solutions.
4.2. Genetic engineering: Enhance of chondrogenic potencial beyond biochemical signals
and functionalized scaffolds
4.2.1. SOX9: The key regulator of the chondrogenic process
Given  the  low  regenerative  capacity  of  the  AC,  it  is  vital  find  ways  to  increase  the
chondrogenic potential of bioimplants designed. Today, not only can enhance the biochem‐
ical  environment  biomaterials  and  implants,  but  genetic  engineering  can  increase  the
potential of MSCs used, changing their gene expression patterns from "inside". For this, it
is  important  to  consider  transcription  factors  and  their  intracellular  signaling  cascades.
Perhaps  the  most  studied of  these  factors  is  SOX9,  considered the  key regulator  of  the
chondrogenic  process  (Bi  et  al.,  1999).  The expression of  SOX9 is  upregulated by mem‐
bers of  the FGFs,  TGF-βs and BMPs, all  of  them widely used chondroinducers.  In turn,
SOX9 is responsible for regulating SOX5, SOX6 and activating the expression of collagens
type II, VI, IX and XI, the proteoglycans Aggrecan, Byglican and Perlecan and important
binding proteins as COMP (Quintana et al., 2009) (Fig. 7).
On the other hand, during skeletogenesis, SOX9 is responsible for the osteochondroprogeni‐
tors differentiation into chondroblasts and not into osteoblasts to direct and indirect repression
of RUNX2 (the main regulator of osteogenic differentiation) favoring the endochondral
ossification (Zhou et al., 2006).
4.2.2. Transfection of SOX9 as an activator of chodrogenesis
The application of these regulatory genes on regenerative design strategies could be useful
to increase both specificity and efficiency of the bioimplants. This opens the possibility of
using not only functionalized biocompatible scaffolds, but also cells previously treated to
have a higher chondrogenic potential. In a recent study, human MSCs are transfected with
a nonviral vector plasmid complexed with SOX9 cDNA in order to induce chondrogene‐
sis. Micromass culture and transplantation into nude mice of control and transfected cells
were made. Both procedures showed increased levels of mRNA for COL2A1, Aggrecan and
COMP;  increased  GAG  content;  alcian  blue  staining  positive  and  detection  of  type  II
collagen and Aggrecan by immunofluorescence, all of the cells transfected with respect to
control.  Similar  results  were achieved using a viral  vector transfection of  SOX9 (Fig.  8).
Additionally, this group demonstrated that transfection of the gene, in addition to induc‐
ing  chondrogenesis,  reduces  the  levels  of  markers  of  hypertrophy,  osteogenesis  and
adipogenesis, thereby inhibiting the possibility that the human MSCs to differentiate into
these mesenchymal lineages (Venkatesan et al., 2012).
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Figure 8. Schematic diagram of SOX9 gene transfection using a modified and non-modified biodegradable nanopar‐
ticles, an example of Non-viral transfection. During hMSCs transfection, nanoparticles interact with the negatively
charged lipid bilayers and are influxed into endosomes and destabilized, resulting in the release of the transfected
genes into the cytosol. From the same authors, published by Biomaterials 32(1): 268–278. Copyright 2011
Figure 7. Upstream and downstream regulation of Sox9. From the same authors, published by Tissue engineering.
Part B, Reviews 15(1): 29–41. Copyright 2009
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The possibility of genetically engineering the different types of MSCs used in cartilage
regeneration is a promising tool for increasing chondrogenic capacity and, consequently,
improving future regeneration bioimplants. A deepest and detailed knowledge of gene
regulation involved in the process and their possible clinical utilities will lead the way of
successful recapitulation of AC morphogenesis through MSCs differentiation.
5. Commercial and industrial translations in tissue engineering
Applications for TE and biomaterials were originally limited to prosthetic devices and surgical
manipulation of tissues but now include development of biomaterial scaffolds, bone/cartilage
engineering, tissue-engineered blood vessels and wound healing, among other fields.
As an industry, it could significantly contribute to economic growth if products are success‐
fully commercialized. However, to date, relatively few products have reached the market
owing to a variety of barriers, including a lack of funding and regulatory hurdles. Policy
interventions, including increased translational government funding, adaptation of policies,
and regulatory clarity, would likely improve the general outcomes for the regenerative
medicine industry.
The technical challenges of TE are, of course, intellectually and scientifically interesting and
can add substantial and previously unattainable knowledge to our understanding of biological
systems (Mansbridge et al., 2006). TE models of biological systems can even provide insight
into pathologic processes. However, perhaps the major attraction of academic researchers and
industrial organizations to this field is the potential of the technology to be readily converted
to clinical applications. For this to happen, the technology almost always will be transferred
from an academic environment to an industrial organization that will lead the comprehensive
translational studies and convert scientific observations into a manufactured product.
As s technology, TE has been shown to be feasible in vitro and in vivo, but the true demonstra‐
tion of the potential value of the technology is in its clinical applications. Although the field is
still in its infancy, there are already tissue-engineered products on the market, addressing
previously unmet clinical needs in wound care and in orthopedics and demonstrating that the
attractiveness and motivation of the field is justified. Perhaps one of the next major challenges
is demonstration that the technology can lead to commercially feasible products, with
manageable investment, product development costs, and time to market and, finally, a revenue
generation that justifies the expense. The close connection between new technology, clinically
effective treatment, and commercially feasible product is obvious and is no better demon‐
strated than in TE. All three of these areas, each complex in itself, must be aligned and achieved
before TE can be regarded as successful.
5.1. Product development pathway
To appreciate the challenge of developing a tissue-engineered product, it is useful to first
understand in general terms the various processes that must be completed (Fig. 9). The
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development of a product through to approval, manufacture, and marketing is complex, and
most companies (within and outside health care) use a staged process to ensure efficient and
effective product development. The general scheme that applies for health care products
(devices, biologics, or drugs) is outlined in the figure. These stages encompass all the activities
that are required to develop a product through to the market. This integrated product
development process can be customized to be appropriate for the development of products
addressing repair and regeneration.
Figure 9. The general product development pathway used to develop tissue-engineered products
Patient protection for an individual product is a critical feature of product development.
Developing new patents is costly, the outcome is uncertain, and it must occur near the
beginning of product development. The limited time for patent protection (usually 10 years
from initial submission) requires that the product development pathway be followed in an
efficient manner; otherwise, patent protection will be lost by the time profitability arrives.
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